CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data ...
Highlights included at least 9% EPS growth each year from 2026 to 2030, a five-year capital plan of $73 billion through 2030, which supports average annual rate base growth of 9%, and a financing plan ...
TOKYO -- Japan's Financial Services Agency is considering allowing members of banking groups to launch a cryptocurrency asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback